Home / Public Antibody Sequence Database / Pembrolizumab PUBLIC ANTIBODY SEQUENCE · PSC-PD1-001 Pembrolizumab antibody sequence PD-1 / CD279 · PDCD1
A high-demand reference antibody for immune-checkpoint research and flow-based binding or competition assays.
PD-1 CD279 PDCD1 Whole mAb IgG4
Project planning Technical review required Scope and timing are confirmed only after the sequence, construct, labeling plan and requested deliverables have been assessed.
Ask about expression and labeling VH · Heavy chain variable region 120 aa
QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSVL · Light chain variable region 111 aa
EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRecord information
Antibody name Pembrolizumab
Target PD-1 / CD279
Gene symbol PDCD1
Molecular format Whole mAb
Heavy-chain isotype IgG4
Light-chain type Kappa
Project code PSC-PD1-001 Alternate names Keytruda · MK-3475 · Lambrolizumab
RESEARCH USE Suggested research applications PD-1 binding detection Competitive blocking Flow cytometry Method control FLUORESCENT OPTIONS Suggested starting labels SF488 PE APC UV421
Dye selection can be adjusted for instrument lasers, co-expression intensity and panel design. Final selection is confirmed during project assessment.
DELIVERABLE Optional project scope Sequence review and construct design Recombinant expression and purification Fluorescent conjugation and free-dye removal Concentration, appearance and agreed basic quality checks START FROM THIS SEQUENCE Start a project from this public sequence Submit the intended antibody format, scale, fluorophore and application. We will first confirm the technical route and delivery boundaries.
Use and intellectual-property boundaries A public sequence does not imply freedom to operate or a commercial license. This record supports research search and project discussion. Customers should complete patent, licensing and freedom-to-operate assessment for the intended use. Antibody names and related trademarks belong to their respective owners; this page does not imply affiliation with or authorization from the originator company.